Hepatobiliary membrane transporters in primary biliary cirrhosis

Hepatology Research

Volumn 42, Issue 2, 2012, Pages 120-130

  Takeyama, Yasuaki ^a   Sakisaka, Shotaro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

ABC transporters; Hepatobiliary transporters; Nuclear hormone receptor; Primary biliary cirrhosis

Indexed keywords

ABC TRANSPORTER A1; BILE SALT; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; ORGANIC ANION TRANSPORTER; ORGANIC SOLUTE TRANSPORTER ALPHA; ORGANIC SOLUTE TRANSPORTER BETA; SODIUM TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; UNCLASSIFIED DRUG;

ADAPTATION; BASOLATERAL MEMBRANE; BILE; BILE SECRETION; CELL MEMBRANE TRANSPORT; CELL SURFACE; HEPATOBILIARY SYSTEM; HUMAN; LIVER CELL; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SOLUTE;

EID: 84855970257     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00912.x     Document Type: Review

References (64)

1. Kosters A, Karpen SJ. Bile acid transporters in health and disease. Xenobiotica 2008; 38: 1043-71.
2. Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997; 25: 1077-84.
3. Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 1997; 26: 1399-405.
4. Sakisaka S, Kawaguchi T, Taniguchi E etal. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2001; 33: 1460-8.
5. Sakisaka S, Koga H, Sasatomi K etal. Ursodeoxycholic acid reduces expression of heat shock proteins in primary biliary cirrhosis. Liver 2000; 20: 78-87.
6. Suzuki N, Irie M, Iwata K etal. Altered expression of alkaline phosphatase (ALP) in the liver of primary biliary cirrhosis (PBC) patients. Hepatol Res 2006; 35: 37-44.
7. Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 2005; 129: 735-40.
8. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-27.
9. Zollner G, Fickert P, Silbert D etal. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003; 38: 717-27.
10. Kullak-Ublick GA, Beuers U, Fahney C, Hagenbuch B, Meier PJ, Paumgartner G. Identification and functional characterization of the promoter region of the human organic anion transporting polypeptide gene. Hepatology 1997; 26: 991-7.
11. Jung D, Podvinec M, Meyer UA etal. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 2002; 122: 1954-66.
12. Oswald M, Kullak-Ublick GA, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 2001; 21: 247-53.
13. Jung D, Kullak-Ublick GA. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 2003; 37: 622-31.
14. Geier A, Martin IV, Dietrich CG etal. Hepatocyte nuclear factor-4alpha is a central transactivator of the mouse Ntcp gene. Am J Physiol Gastrointest Liver Physiol 2008; 295: G226-233.
15. Eloranta JJ, Jung D, Kullak-Ublick GA. The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol Endocrinol 2006; 20: 65-79.
16. Shefer S, Hauser S, Bekersky I, Mosbach EH. Biochemical site of regulation of bile acid biosynthesis in the rat. J Lipid Res 1970; 11: 404-11.
17. Chawla A, Saez E, Evans RM. Don't know much bile-ology. Cell 2000; 29 (103): 1-4.
18. Takeyama Y, Kanegae K, Inomata S etal. Sustained upregulation of sodium taurocholate cotransporting polypeptide and bile salt export pump and downregulation of cholesterol 7alpha-hydroxylase in the liver of patients with end-stage primary biliary cirrhosis. Med Mol Morphol 2010; 43: 134-8.
19. Goodwin B, Jones SA, Price RR etal. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6: 517-26.
20. Xie W, Radominska-Pandya A, Shi Y etal. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 2001; 98: 3375-80.
21. Marschall HU, Wagner M, Bodin K etal. Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J Lipid Res 2006; 47: 582-92.
22. Saini SP, Sonoda J, Xu L etal. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol 2004; 65: 292-300.
23. Stedman C, Robertson G, Coulter S, Liddle C. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J Biol Chem 2004; 279: 11336-43.
24. Chen YH, Hong IC, Kuo KK, Hsu HK, Hsu C. Role of retinoid-X receptor-alpha in the suppression of rat bile acid coenzyme A-amino acid N-acyltransferase in liver during sepsis. Shock 2007; 28: 65-70.
25. Miyata M, Matsuda Y, Tsuchiya H etal. Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase. Drug Metab Pharmacokinet 2006; 21: 315-23.
26. Zollner G, Wagner M, Fickert P etal. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 2007; 27: 920-9.
27. Boyer JL. Adaptive regulation of hepatocyte transporters in cholestasis. In: Irwin M. Arias, ed. The Liver. West Sussex, UK: John Wiley & Sons, Ltd, 2009; 681-702.
28. Alnouti Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci 2009; 108: 225-46.
29. Miura R, Tanaka A, Takikawa H. Urinary bile acid sulfate levels in patients with primary biliary cirrhosis. Hepatol Res 2011; 41: 358-63.
30. Jansen PL, Muller M. Early events in sepsis-associated cholestasis. Gastroenterology 1999; 116: 486-8.
31. Keitel V, Vogt C, Haussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severeeintrahepatic cholestasis of pregnancy. Gastroenterology 2006; 131: 624-9.
32. Pauli-Magnus C, Lang T, Meier Y etal. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004; 14: 91-102.
33. Strautnieks SS, Bull LN, Knisely AS etal. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998; 20: 233-8.
34. Lang C, Meier Y, Stieger B etal. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007; 17: 47-60.
35. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002; 123: 1649-58.
36. Funk C, Pantze M, Jehle L etal. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 2001; 167: 83-98.
37. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001; 59: 627-35.
38. Barnes SN, Aleksunes LM, Augustine L etal. Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab Dispos 2007; 35: 1963-9.
39. Takeyama Y, Uehara Y, Inomata S etal. Alternative transporter pathways in patients with untreated early-stage and late-stage primary biliary cirrhosis. Liver Int 2009; 29: 406-14.
40. Makishima M, Okamoto AY, Repa JJ etal. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.
41. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731-44.
42. Wolters H, Elzinga BM, Baller JF etal. Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice. J Hepatol 2002; 37: 556-63.
43. Pauli-Magnus C, Kerb R, Fattinger K etal. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2004; 39: 779-91.
44. Nakamuta M, Fujino T, Yada R etal. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. Int J Clin Pharmacol Ther 2010; 48: 22-8.
45. Enjoji M, Yada R, Fujino T etal. The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Hepatol Int 2009; 3: 490-6.
46. Zollner G, Fickert P, Zenz R etal. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001; 33: 633-46.
47. Dumoulin FL, Reichel C, Sauerbruch T, Spengler U. Semiquantitation of intrahepatic MDR3 mRNA levels by reverse transcription/competitive polymerase chain reaction. J Hepatol 1997; 26: 852-6.
48. Shoda J, Okada K, Inada Y etal. Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res 2007; 37: 548-56.
49. Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003; 38: 573-8.
50. Hashimoto K, Uchiumi T, Konno T etal. Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology 2002; 36: 1236-45.
51. Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol 2003; 200: 553-60.
52. Chen W, Cai SY, Xu S, Denson LA, Soroka CJ, Boyer JL. Nuclear receptors RXRalpha: RARalpha are repressors for human MRP3 expression. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1221-1227.
53. Chai J, Luo D, Wu X etal. Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis. J Gastrointest Surg 2011; 15: 996-1004.
54. Denk GU, Soroka CJ, Takeyama Y, Chen WS, Schuetz JD, Boyer JL. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 2004; 40: 585-91.
55. Boyer JL, Trauner M, Mennone A etal. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1124-1130.
56. Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab 2010; 11: 603-17.
57. Vander Borght S, Libbrecht L, Katoonizadeh A etal. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J Histochem Cytochem 2006; 54: 1051-9.
58. Mennone A, Soroka CJ, Harry KM, Boyer JL. Role of breast cancer resistance protein in the adaptive response to cholestasis. Drug Metab Dispos 2010; 38: 1673-8.
59. Takeyama Y, Uehara Y, Anan A etal. Hepatic ABCA1 transporter is up-regulated in bile duct ligation (BDL) with LPS-treated rats and in PBC patients. J Hepatol 2005; 42: 239.
60. Medina JF, Martinez A, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997; 25: 12-7.
61. Prieto J, Qian C, Garcia N, Diez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology 1993; 105: 572-8.
62. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol 2009; 51: 565-80.
63. Boyer JL. Cholestasis: genetic and acquired. Semin Liver Dis 2010; 30: 113-5.
64. Lindor KD. Farnesoid X receptor agonists for primary biliary cirrhosis. Curr Opin Gastroenterol 2011; 27: 285-8.